Marinus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders.
The last earnings update was 55 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Marinus Pharmaceuticals. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Marinus Pharmaceuticals's earnings available for a low price, and how does
this compare to other companies in the same industry?
Marinus Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.
Unable to determine if Marinus Pharmaceuticals is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Marinus Pharmaceuticals's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Marinus Pharmaceuticals's finances.
The net worth of a company is the difference between its assets and liabilities.
Marinus Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Marinus Pharmaceuticals's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Marinus Pharmaceuticals's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Debt is not covered by short term assets, assets are -1.4157515788602E+17x debt.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Analysts Expect Breakeven For Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS)
Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS): Marinus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. … I’ve put together a brief outline of industry analyst expectations for MRNS, its year of breakeven and its implied growth rate. … See our latest analysis for Marinus Pharmaceuticals MRNS is bordering on breakeven, according to the 8 Pharmaceuticals analysts.
What Kind Of Shareholders Own Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS)?
Marinus Pharmaceuticals is not a large company by global standards. … It has a market capitalization of US$198m, which means it wouldn't have the attention of many institutional investors. … institutional investors have bought into the company.
What Kind Of Shareholders Own Marinus Pharmaceuticals Inc (NASDAQ:MRNS)?
A look at the shareholders of Marinus Pharmaceuticals Inc (NASDAQ:MRNS) can tell us which group is most powerful. … Institutions will often hold stock in bigger companies, and we expect to see insiders owning a noticeable percentage of the smaller ones. … Marinus Pharmaceuticals is a smaller company with a market capitalization of US$189m, so it may still be flying under the radar of many institutional investors.
When Can We Expect A Profit From Marinus Pharmaceuticals Inc (NASDAQ:MRNS)?
Marinus Pharmaceuticals Inc's (NASDAQ:MRNS):. … The company’s loss has recently broadened since it announced a -US$19m loss in the full financial year, compared to the latest trailing-twelve-month loss of -US$24m, moving it further away from breakeven. … View our latest analysis for Marinus Pharmaceuticals
Who Are The Major Shareholders In Marinus Pharmaceuticals Inc (NASDAQ:MRNS)?
In this article, I'm going to take a look at Marinus Pharmaceuticals Inc’s (NASDAQ:MRNS) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject among investors. … Although this is an important factor for long-term investors, many investors can also be impacted by institutional presence and their high-volume trading. … Check out our latest analysis for Marinus Pharmaceuticals
Marinus Pharmaceuticals Inc (NASDAQ:MRNS) Is Expected To Breakeven
Marinus Pharmaceuticals Inc's (NASDAQ:MRNS):. … Marinus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. … The US$303.50m market-cap posted a loss in its most recent financial year of -US$18.90m and a latest trailing-twelve-month loss of -US$19.46m leading to an even wider gap between loss and breakeven
Should You Buy Marinus Pharmaceuticals Inc (NASDAQ:MRNS) At $5.51?
Let’s take a look at Marinus Pharmaceuticals’s outlook and value based on the most recent financial data to see if there are any catalysts for a price change. … I find that Marinus Pharmaceuticals’s ratio of 3.59x is trading slightly above its industry peers’ ratio of 2.69x, which means if you buy Marinus Pharmaceuticals today, you’d be paying a relatively fair price for it. … And if you believe that Marinus Pharmaceuticals should be trading at this level in the long run, there’s only an insignificant downside when the price falls to its real value.
At $6.35, Is Marinus Pharmaceuticals Inc (MRNS) A Buy?
So, could MRNS still be trading at a low price relative to its actual value? … And if you believe MRNS should be trading in this range, then there isn’t much room for the share price grow beyond what it’s currently trading. … If you are no longer interested in Marinus Pharmaceuticals, you can use our free platform to see my list of over 50 other stocks with a high growth potential.
Marinus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three dose forms, including intravenous (IV), oral capsule, and oral liquid for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company’s ganaxolone product candidate exhibits anti-seizure, anti-depression, and anti-anxiety actions through its effects on synaptic and extrasynaptic GABAA receptors. It is also developing ganaxolone for cyclin-ependent kinase-like 5 deficiency disorder, PCDH19-related epilepsy, postpartum depression, refractory status epilepticus, and other indications. Marinus Pharmaceuticals, Inc. has a collaboration agreement with NovaMedica, LLC; and license and supply agreements with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc. The company was founded in 2003 and is based in Radnor, Pennsylvania.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.